Database Query Results : Iron, ,

Fe, Iron: Click to Expand ⟱
Features:
Iron plays a dual and highly context-dependent role in cancer biology. It is essential for tumor proliferation due to its requirement in DNA synthesis (ribonucleotide reductase), mitochondrial respiration, and cell cycle progression. Many cancers exhibit increased iron uptake (↑ transferrin receptor, TfR1) and decreased iron export (↓ ferroportin), leading to intracellular iron accumulation that supports rapid growth. However, excess labile iron also promotes oxidative stress through Fenton chemistry (Fe²⁺ + H₂O₂ → •OH), contributing to DNA damage and genomic instability.

A major therapeutic concept is ferroptosis, an iron-dependent form of regulated cell death driven by lipid peroxidation. Tumors with high iron dependency can be selectively vulnerable to ferroptosis induction. Conversely, chronic iron overload may promote tumor initiation through ROS-mediated mutagenesis and inflammatory signaling.
Thus, iron sits at a metabolic intersection:
-Pro-tumor when supporting proliferation and ROS-driven mutation
-Anti-tumor when leveraged to trigger ferroptotic cell death

Iron biology in cancer is best understood through three axes:
-Iron uptake/storage/export balance
-ROS and oxidative stress dynamics
-Ferroptosis susceptibility
Iron is a vital trace element that plays essential roles in various physiological processes. Its importance stems from its involvement in oxygen transport, energy production, DNA synthesis, and numerous enzymatic reactions.
– Iron is a critical component of hemoglobin in red blood cells, enabling the binding and transport of oxygen from the lungs to tissues.
– Iron participates in redox reactions due to its ability to alternate between ferrous (Fe²⁺) and ferric (Fe³⁺) states.

Tumor cells often require increased iron to support their rapid proliferation and metabolic demands. – Elevated iron availability can promote DNA synthesis, cell division, and tumor growth.

• Promotion of Reactive Oxygen Species (ROS) Formation:
– Iron’s redox-active nature, while important for normal cell functions, can also lead to the generation of reactive oxygen species via reactions such as the Fenton reaction:
Fe²⁺ + H₂O₂ → Fe³⁺ + •OH + OH⁻
– The hydroxyl radicals (•OH) produced are highly reactive and can cause oxidative damage to cellular components (DNA, proteins, lipids).
– This oxidative damage may contribute to genomic instability, mutations, and the progression of cancer.

Cancer cells often exhibit increased iron dependency, targeting iron metabolism is a strategy that is being explored for cancer therapy.
– Approaches include the use of iron chelators to sequester iron and limit its availability to tumor cells, thereby inhibiting their growth.
– Alternatively, therapies may aim to exploit iron’s capacity to generate toxic ROS beyond a threshold that cancer cells can manage, leading to selective cell death.

Iron (Fe) – Cancer Pathway Matrix

Rank Pathway / Axis Cancer Context Normal Tissue Context TSF Primary Effect Notes / Interpretation
1 Iron Uptake (TfR1 ↑) Transferrin receptor ↑; iron import ↑; supports rapid proliferation Regulated iron homeostasis G Pro-growth metabolic support Many tumors upregulate TfR1 to fuel DNA synthesis and mitochondrial metabolism.
2 Ribonucleotide Reductase DNA synthesis ↑; cell cycle progression ↑ Required for normal division R, G Proliferation driver Iron is a required cofactor for ribonucleotide reductase.
3 Fenton Chemistry → ROS ROS ↑; DNA damage ↑; genomic instability ↑ Oxidative injury risk if overload R, G Mutagenic driver Fe²⁺ catalyzes hydroxyl radical formation; promotes tumor initiation and progression.
4 Ferroptosis (iron-dependent lipid peroxidation) Lipid ROS ↑; ferroptotic death if GPX4 overwhelmed Normally suppressed by antioxidant systems R, G Therapeutic vulnerability High iron tumors may be selectively sensitive to ferroptosis induction.
5 Ferritin Storage Ferritin ↑ in many cancers; buffers labile iron pool Physiologic iron storage G Iron buffering / adaptation High ferritin can protect tumor cells from oxidative death.
6 Ferroportin (Export) ↓ Iron retention ↑; tumor growth support Maintains systemic balance G Pro-growth adaptation Reduced iron export correlates with aggressive phenotypes in some cancers.
7 NRF2 Axis NRF2 ↑ may increase ferritin and antioxidant defenses Protective oxidative stress response G Adaptive survival pathway NRF2 activation can protect against iron-driven oxidative stress and ferroptosis.
8 Inflammation (IL-6 / Hepcidin) Iron sequestration altered; tumor microenvironment modulation Systemic iron regulation G Microenvironmental modifier Inflammatory cytokines alter iron distribution and availability.
9 Anemia / Iron Depletion Hypoxia signaling ↑ (HIF-1α); therapy resistance context Fatigue, impaired oxygen delivery G Clinical constraint Iron deficiency anemia may worsen hypoxia-driven tumor aggressiveness.

Time-Scale Flag (TSF):
P = 0–30 min (redox reactions)
R = 30 min–3 hr (ROS signaling shifts)
G = >3 hr (proliferation, ferroptosis sensitivity, adaptation)



Scientific Papers found: Click to Expand⟱
4018- FulvicA,  Fe,    Inhibitory Impacts of Fulvic Acid-Coated Iron Oxide Nanoparticles on the Amyloid Fibril Aggregations
- in-vivo, AD, NA
*Inflam↓, *Aβ↓,
1762- MF,  Fe,    Triggering the apoptosis of targeted human renal cancer cells by the vibration of anisotropic magnetic particles attached to the cell membrane
- in-vitro, RCC, NA
Dose∅, Apoptosis↑, Casp↑, tumCV↓, Casp3↑, Casp7↑, Ca+2↑, Cyt‑c↑,
1737- MFrot,  Fe,  MF,    Feature Matching of Microsecond-Pulsed Magnetic Fields Combined with Fe3O4 Particles for Killing A375 Melanoma Cells
- in-vitro, MB, A375
Dose∅, tumCV↓,
3292- SIL,  Fe,    Anti-tumor activity of silymarin nanoliposomes in combination with iron: In vitro and in vivo study
- in-vitro, BC, 4T1 - in-vivo, BC, 4T1
*antiOx↑, ROS↑, OS↑, Weight↑, TumVol↓, eff↑, Fenton↑,
629- VitC,  Cu,  Fe,    The antioxidant ascorbic acid mobilizes nuclear copper leading to a prooxidant breakage of cellular DNA: implications for chemotherapeutic action against cancer
- in-vitro, NA, NA
ROS↑, DNAdam↑, NAD↓,

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 5

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress ⓘ

Fenton↑, 1,   ROS↑, 2,  

Core Metabolism/Glycolysis ⓘ

NAD↓, 1,  

Cell Death ⓘ

Apoptosis↑, 1,   Casp↑, 1,   Casp3↑, 1,   Casp7↑, 1,   Cyt‑c↑, 1,  

Transcription & Epigenetics ⓘ

tumCV↓, 2,  

DNA Damage & Repair ⓘ

DNAdam↑, 1,  

Migration ⓘ

Ca+2↑, 1,  

Drug Metabolism & Resistance ⓘ

Dose∅, 2,   eff↑, 1,  

Functional Outcomes ⓘ

OS↑, 1,   TumVol↓, 1,   Weight↑, 1,  
Total Targets: 16

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress ⓘ

antiOx↑, 1,  

Immune & Inflammatory Signaling ⓘ

Inflam↓, 1,  

Protein Aggregation ⓘ

Aβ↓, 1,  
Total Targets: 3

Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:104  Target#:%  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page